89bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases. The company is headquartered in the United States with operations in Israel.
Its lead program, pegozafermin, is a long-acting analog of the endogenous hormone FGF21 in clinical development for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to extend half-life and enhance biological activity to address key drivers of these conditions, including dyslipidemia, insulin resistance, inflammation, and fibrosis.
